Highlights
The global Cancer Biological Therapy market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Cancer Biological Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Cancer Biological Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Cancer Biological Therapy in Hospitals is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Cancer Biological Therapy include ELI Lilly, Sanofi, Merck, Bayer, Roche, Novartis International, Pfizer, Bristol-Myers Squibb and Seattle Genetics, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Cancer Biological Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cancer Biological Therapy.
The Cancer Biological Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cancer Biological Therapy market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Cancer Biological Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
ELI Lilly
Sanofi
Merck
Bayer
Roche
Novartis International
Pfizer
Bristol-Myers Squibb
Seattle Genetics
Amgen
Takeda Pharmaceuticals
GlaxoSmithKline
Spectrum Pharmaceuticals
Celgene Corporation
AstraZeneca, Plc.
Otsuka
Eisai
Abbvie
Incyte
Segment by Type
Monoclonal Antibodies
Vaccines
Cancer Growth Blockers
Blood Cell Growth Factors
Segment by Application
Hospitals
Diagnostic Laboratories
Research & Academic Laboratories
Pharmaceutical & Biotechnology Companies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Cancer Biological Therapy companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Cancer Biological Therapy 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Monoclonal Antibodies
1.2.3 Vaccines
1.2.4 Cancer Growth Blockers
1.2.5 Blood Cell Growth Factors
1.3 麻豆原创 by Application
1.3.1 Global Cancer Biological Therapy 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals
1.3.3 Diagnostic Laboratories
1.3.4 Research & Academic Laboratories
1.3.5 Pharmaceutical & Biotechnology Companies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Cancer Biological Therapy 麻豆原创 Perspective (2018-2029)
2.2 Cancer Biological Therapy Growth Trends by Region
2.2.1 Global Cancer Biological Therapy 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Cancer Biological Therapy Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Cancer Biological Therapy Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Cancer Biological Therapy 麻豆原创 Dynamics
2.3.1 Cancer Biological Therapy Industry Trends
2.3.2 Cancer Biological Therapy 麻豆原创 Drivers
2.3.3 Cancer Biological Therapy 麻豆原创 Challenges
2.3.4 Cancer Biological Therapy 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Cancer Biological Therapy Players by Revenue
3.1.1 Global Top Cancer Biological Therapy Players by Revenue (2018-2023)
3.1.2 Global Cancer Biological Therapy Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Cancer Biological Therapy 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Cancer Biological Therapy Revenue
3.4 Global Cancer Biological Therapy 麻豆原创 Concentration Ratio
3.4.1 Global Cancer Biological Therapy 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Cancer Biological Therapy Revenue in 2022
3.5 Cancer Biological Therapy Key Players Head office and Area Served
3.6 Key Players Cancer Biological Therapy Product Solution and Service
3.7 Date of Enter into Cancer Biological Therapy 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Cancer Biological Therapy Breakdown Data by Type
4.1 Global Cancer Biological Therapy Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Cancer Biological Therapy Forecasted 麻豆原创 Size by Type (2024-2029)
5 Cancer Biological Therapy Breakdown Data by Application
5.1 Global Cancer Biological Therapy Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Cancer Biological Therapy Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Cancer Biological Therapy 麻豆原创 Size (2018-2029)
6.2 North America Cancer Biological Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
6.4 North America Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Cancer Biological Therapy 麻豆原创 Size (2018-2029)
7.2 Europe Cancer Biological Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
7.4 Europe Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Cancer Biological Therapy 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Cancer Biological Therapy 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Cancer Biological Therapy 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Cancer Biological Therapy 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Cancer Biological Therapy 麻豆原创 Size (2018-2029)
9.2 Latin America Cancer Biological Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Cancer Biological Therapy 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Cancer Biological Therapy 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Cancer Biological Therapy 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Cancer Biological Therapy 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 ELI Lilly
11.1.1 ELI Lilly Company Detail
11.1.2 ELI Lilly Business Overview
11.1.3 ELI Lilly Cancer Biological Therapy Introduction
11.1.4 ELI Lilly Revenue in Cancer Biological Therapy Business (2018-2023)
11.1.5 ELI Lilly Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Cancer Biological Therapy Introduction
11.2.4 Sanofi Revenue in Cancer Biological Therapy Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Cancer Biological Therapy Introduction
11.3.4 Merck Revenue in Cancer Biological Therapy Business (2018-2023)
11.3.5 Merck Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Cancer Biological Therapy Introduction
11.4.4 Bayer Revenue in Cancer Biological Therapy Business (2018-2023)
11.4.5 Bayer Recent Development
11.5 Roche
11.5.1 Roche Company Detail
11.5.2 Roche Business Overview
11.5.3 Roche Cancer Biological Therapy Introduction
11.5.4 Roche Revenue in Cancer Biological Therapy Business (2018-2023)
11.5.5 Roche Recent Development
11.6 Novartis International
11.6.1 Novartis International Company Detail
11.6.2 Novartis International Business Overview
11.6.3 Novartis International Cancer Biological Therapy Introduction
11.6.4 Novartis International Revenue in Cancer Biological Therapy Business (2018-2023)
11.6.5 Novartis International Recent Development
11.7 Pfizer
11.7.1 Pfizer Company Detail
11.7.2 Pfizer Business Overview
11.7.3 Pfizer Cancer Biological Therapy Introduction
11.7.4 Pfizer Revenue in Cancer Biological Therapy Business (2018-2023)
11.7.5 Pfizer Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Cancer Biological Therapy Introduction
11.8.4 Bristol-Myers Squibb Revenue in Cancer Biological Therapy Business (2018-2023)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Seattle Genetics
11.9.1 Seattle Genetics Company Detail
11.9.2 Seattle Genetics Business Overview
11.9.3 Seattle Genetics Cancer Biological Therapy Introduction
11.9.4 Seattle Genetics Revenue in Cancer Biological Therapy Business (2018-2023)
11.9.5 Seattle Genetics Recent Development
11.10 Amgen
11.10.1 Amgen Company Detail
11.10.2 Amgen Business Overview
11.10.3 Amgen Cancer Biological Therapy Introduction
11.10.4 Amgen Revenue in Cancer Biological Therapy Business (2018-2023)
11.10.5 Amgen Recent Development
11.11 Takeda Pharmaceuticals
11.11.1 Takeda Pharmaceuticals Company Detail
11.11.2 Takeda Pharmaceuticals Business Overview
11.11.3 Takeda Pharmaceuticals Cancer Biological Therapy Introduction
11.11.4 Takeda Pharmaceuticals Revenue in Cancer Biological Therapy Business (2018-2023)
11.11.5 Takeda Pharmaceuticals Recent Development
11.12 GlaxoSmithKline
11.12.1 GlaxoSmithKline Company Detail
11.12.2 GlaxoSmithKline Business Overview
11.12.3 GlaxoSmithKline Cancer Biological Therapy Introduction
11.12.4 GlaxoSmithKline Revenue in Cancer Biological Therapy Business (2018-2023)
11.12.5 GlaxoSmithKline Recent Development
11.13 Spectrum Pharmaceuticals
11.13.1 Spectrum Pharmaceuticals Company Detail
11.13.2 Spectrum Pharmaceuticals Business Overview
11.13.3 Spectrum Pharmaceuticals Cancer Biological Therapy Introduction
11.13.4 Spectrum Pharmaceuticals Revenue in Cancer Biological Therapy Business (2018-2023)
11.13.5 Spectrum Pharmaceuticals Recent Development
11.14 Celgene Corporation
11.14.1 Celgene Corporation Company Detail
11.14.2 Celgene Corporation Business Overview
11.14.3 Celgene Corporation Cancer Biological Therapy Introduction
11.14.4 Celgene Corporation Revenue in Cancer Biological Therapy Business (2018-2023)
11.14.5 Celgene Corporation Recent Development
11.15 AstraZeneca, Plc.
11.15.1 AstraZeneca, Plc. Company Detail
11.15.2 AstraZeneca, Plc. Business Overview
11.15.3 AstraZeneca, Plc. Cancer Biological Therapy Introduction
11.15.4 AstraZeneca, Plc. Revenue in Cancer Biological Therapy Business (2018-2023)
11.15.5 AstraZeneca, Plc. Recent Development
11.16 Otsuka
11.16.1 Otsuka Company Detail
11.16.2 Otsuka Business Overview
11.16.3 Otsuka Cancer Biological Therapy Introduction
11.16.4 Otsuka Revenue in Cancer Biological Therapy Business (2018-2023)
11.16.5 Otsuka Recent Development
11.17 Eisai
11.17.1 Eisai Company Detail
11.17.2 Eisai Business Overview
11.17.3 Eisai Cancer Biological Therapy Introduction
11.17.4 Eisai Revenue in Cancer Biological Therapy Business (2018-2023)
11.17.5 Eisai Recent Development
11.18 Abbvie
11.18.1 Abbvie Company Detail
11.18.2 Abbvie Business Overview
11.18.3 Abbvie Cancer Biological Therapy Introduction
11.18.4 Abbvie Revenue in Cancer Biological Therapy Business (2018-2023)
11.18.5 Abbvie Recent Development
11.19 Incyte
11.19.1 Incyte Company Detail
11.19.2 Incyte Business Overview
11.19.3 Incyte Cancer Biological Therapy Introduction
11.19.4 Incyte Revenue in Cancer Biological Therapy Business (2018-2023)
11.19.5 Incyte Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
ELI Lilly
Sanofi
Merck
Bayer
Roche
Novartis International
Pfizer
Bristol-Myers Squibb
Seattle Genetics
Amgen
Takeda Pharmaceuticals
GlaxoSmithKline
Spectrum Pharmaceuticals
Celgene Corporation
AstraZeneca, Plc.
Otsuka
Eisai
Abbvie
Incyte
听
听
*If Applicable.
